About iXG | Leaders in Metabolic Biomarker Innovation

About Us

Advancing the understanding of trauma’s impact on health

iXpressGenes is developing solutions designed to provide insights into the body’s response to stress well before traditional symptoms may appear.

Who We Are

Innovative biological research for earlier insight

iXpressGenes is advancing the understanding of trauma's impact on health through innovative biological research. We are developing solutions designed to provide insights into the body's response to stress well before traditional symptoms may appear.

Our pioneering Trauma Autoimmune Indicator™ (TAI) test analyzes RNA biomarkers to reveal connections between mental and physical well-being. We aim to equip healthcare providers with objective data, supporting a more proactive and informed approach to care that seeks to improve long-term wellness outcomes.

Explore TAI Explore APX

What We Do

Pioneering research into the biological impact of trauma

At iXpressGenes, we are pioneering research into the biological impact of trauma. Our work focuses on discovering biomarkers that may provide a new understanding of how stress affects the body's systems.

We are dedicated to advancing science that could one day lead to earlier insights into wellness, moving from a reactive to a more proactive model of understanding health.

Our Team Resources

Why This Test?

A molecular perspective that goes beyond traditional methods

Our approach is rooted in biology. We analyze RNA to understand changes in the immune system's response to stress, providing a molecular perspective that goes beyond traditional methods.

This research is vital because the biological effects of trauma are often not visible. We are developing tools to reveal these hidden patterns, offering objective data for healthcare providers to consider within a full clinical assessment.

By providing this unique window into the body's response, our goal is to contribute to a future where people have more information to address health challenges earlier in their journey. We aim to empower the medical community with deeper biological insights, supporting a more integrated approach to care.

Our Story

Research born from lived reality

On February 10th, 2010, Founder Dr. Joe Ng survived an on-campus shooting in the Biology department at the University of Alabama in Huntsville (UAH). During a staff meeting, Joe’s colleague pulled a handgun and shot her co-workers, killing three of them.

Following the shooting, Joe noticed a spectrum of resilience among the survivors — and the research began.

Leadership

Dr. Joseph (Joe) Ng

Co-Founder & President, iXpressGenes • HudsonAlpha Institute for Biotechnology

Dr. Ng brings deep molecular science to real-world health and performance decision-making. Trained as a biochemist and structural biologist, he has spent his career translating complex biology into practical, measurable insight.

Scientific foundation

PhD in Biochemistry (University of California, Riverside) with postdoctoral research at France’s CNRS, focused on macromolecular crystal growth and X-ray crystallography.

Core expertise

Molecular biology, protein chemistry, and structural analysis to decode protein structure, essential biological functions, and genomics.

What it enables for partners

Research leadership in biomarker discovery across inflammation and stress-related biology — supporting the development of objective tools professionals can integrate into their existing workflows.

Community + collaboration

Instrumental in strengthening Huntsville’s biotech ecosystem through collaboration with UAH’s business school, private companies, and government laboratories.

Business Leadership

The team bringing molecular insight into real-world workflows

Leaders focused on making iXG easy to adopt, simple to deploy, and valuable across clinics, coaches, wellness programs, and platforms.

John Schmitt

CEO

John leads iXG’s strategy and commercialization with a focus on making biomarker testing a practical, revenue-driving layer for partners. He prioritizes clear positioning, fast deployment, and measurable outcomes that strengthen retention and pricing power.

Partner-first go-to-market and deployment focus
Workflow simplicity: easy ordering, kit adoption, and delivery
Outcome-driven: trust, retention, and premium differentiation

Jeremy Bowling

President

Jeremy oversees operations and partner enablement — ensuring iXG deployments run smoothly from ordering to processing to results delivery. His work centers on consistency, quality, and helping partners scale without adding friction.

Operational excellence across ordering, processing, and reporting
Repeatable partner workflows for clinics, coaches, and platforms
Launch support that scales with your business model

Allie Udall

Director of Customer Success

Allie leads partner onboarding and success — helping teams adopt iXG quickly and confidently. She supports rollout, training, and ongoing optimization so partners can drive high utilization, better retention, and a strong client experience.

Onboarding and training designed for rapid adoption
Enablement: talk tracks, delivery flow, and best practices
Ongoing optimization to increase utilization and outcomes

Disclaimer

iXpressGenes panels, including WLR, TAI™ and APX™, were developed and its performance characteristics determined by iXpressGenes in its College of American Pathologists (CAP) accredited laboratory. They have not been cleared or approved by the U.S. Food and Drug Administration (FDA). iXpressGenes Inc. is not a licensed medical provider.

iXpressGenes panels do not diagnose any disease or condition, including PTSD. The panels are not intended to inform treatment decisions. This test provides informational data on biomarker levels for consideration by a qualified healthcare professional within the full context of a patient's clinical evaluation. All interpretations or information provided are derived from peer-reviewed scientific literature and are not a substitute for professional medical advice, diagnosis, or treatment. Patients must consult their physician or licensed healthcare provider before making any medical decisions.